Kalkine has a fully transformed New Avatar.

Orthocell Ltd

Healthcare AU OCC

1.19AUD
-0.01(0.83%)

Last update at 2025-06-20T06:10:00Z

Day Range

1.181.21
LowHigh

52 Week Range

0.351.79
LowHigh

Fundamentals

  • Previous Close 1.20
  • Market Cap292.01M
  • Volume590894
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-10.17842M
  • Revenue TTM6.31M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 4.23M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -9.41056M -11.25054M -11.43142M -9.05557M -8.38037M
Minority interest - - - - -
Net income -6.24818M -9.10659M -9.03702M -6.15103M -5.85221M
Selling general administrative 4.25M 2.24M 3.25M 2.56M 2.02M
Selling and marketing expenses 1.71M 3.30M 1.46M 1.44M 1.28M
Gross profit 3.22M 0.83M 0.39M 0.21M 0.36M
Reconciled depreciation 0.55M 0.35M 0.44M 0.26M 0.22M
Ebit -10.89467M -11.87323M -12.10495M -9.51541M -8.75111M
Ebitda -10.34055M -11.52461M -11.66929M -9.25490M -8.53239M
Depreciation and amortization 0.55M 0.35M 0.44M 0.26M 0.22M
Non operating income net other - - - - -
Operating income -10.28006M -11.52178M -11.63111M -9.17196M -8.75111M
Other operating expenses 14.50M 12.87M 12.65M 9.89M 9.84M
Interest expense - 0.08M 0.67M 0.46M 0.37M
Tax provision -3.16238M -2.14396M -2.39440M -2.90455M -2.52816M
Interest income 0.85M 0.08M 0.20M 0.12M 0.01M
Net interest income 0.85M 0.08M 0.20M 0.12M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.16238M -2.14396M -2.39440M -2.90455M -2.52816M
Total revenue 4.24M 1.53M 1.02M 0.72M 1.09M
Total operating expenses 14.11M 12.70M 12.50M 9.73M 9.11M
Cost of revenue 1.03M 0.70M 0.63M 0.51M 0.73M
Total other income expense net 0.08M 0.19M 0.04M 0.08M 0.37M
Discontinued operations - - - - -
Net income from continuing ops -6.24818M -9.10659M -9.03702M -6.15103M -5.85221M
Net income applicable to common shares -6.24818M -9.10659M -9.03702M -6.15103M -5.85221M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 26.62M 29.61M 37.90M 19.33M 23.17M
Intangible assets 1.05M 1.13M 1.23M 1.32M 1.63M
Earning assets - - - - -
Other current assets 0.00971M 0.17M 0.08M 0.01M 0.06M
Total liab 22.08M 23.46M 27.99M 2.46M 2.27M
Total stockholder equity 4.53M 6.15M 9.90M 16.87M 20.90M
Deferred long term liab - - - - -
Other current liab 1.50M 1.17M 2.63M 0.30M 0.33M
Common stock 62.22M 57.90M 57.48M 55.78M 53.67M
Capital stock 62.22M 57.90M 57.48M 55.78M 53.67M
Retained earnings -65.62639M -59.08434M -53.48536M -45.11498M -36.14681M
Other liab - 18.54M 20.79M 0.01M 0.01M
Good will - - - - -
Other assets - - - - -
Cash 20.61M 24.82M 11.02M 16.33M 20.44M
Cash and equivalents - 24.82M 11.02M 16.33M 20.44M
Total current liabilities 5.31M 4.53M 6.82M 1.93M 1.86M
Current deferred revenue 2.30M 2.30M 0.78M 0.63M 0.63M
Net debt -19.92475M -24.25566M -10.51399M -15.70719M -19.94073M
Short term debt 0.15M 0.18M 0.12M 0.11M 0.11M
Short long term debt - - - - -
Short long term debt total 0.69M 0.56M 0.51M 0.62M 0.50M
Other stockholder equity - -1.89339M -7.07045M -13.74093M -20.60768M
Property plant equipment - 1.61M 1.40M 0.93M 0.74M
Total current assets 23.01M 26.87M 35.26M 17.07M 20.81M
Long term investments - - - - -
Net tangible assets - 5.02M 8.67M 15.55M 19.27M
Short term investments - - - - -
Net receivables 1.21M 0.84M 23.55M 0.26M 0.25M
Long term debt - - - - -
Inventory 1.18M 1.03M 0.61M 0.47M 0.05M
Accounts payable 1.35M 0.88M 3.28M 0.89M 0.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.94M 7.34M 5.91M 6.21M 3.38M
Additional paid in capital - - - - -
Common stock total equity - - - - 53.67M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.05M -2.73911M -2.63184M -2.25797M -0.00000M
Deferred long term asset charges - - - - -
Non current assets total 3.61M 2.74M 2.63M 2.26M 2.37M
Capital lease obligations 0.69M 0.56M 0.51M 0.62M 0.50M
Long term debt total - 0.38M 0.39M 0.51M 0.39M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.63156M -0.53502M -0.18852M -0.05520M -0.36874M
Change to liabilities -2.98300M 25.27M 0.11M -0.75062M 0.38M
Total cashflows from investing activities -0.63156M -0.53502M -0.18852M -0.05520M -0.36874M
Net borrowings -0.16461M -0.14682M -0.11545M -0.11545M -0.11545M
Total cash from financing activities -0.16461M 1.49M 0.71M 14.52M 12.88M
Change to operating activities 0.22M 0.10M -0.08837M -0.27047M -0.29214M
Net income -6.24818M -9.10659M -9.03702M -6.15103M -5.85221M
Change in cash 13.80M -5.30736M -4.11270M 9.21M 8.33M
Begin period cash flow 11.02M 16.33M 20.44M 11.24M 2.91M
End period cash flow 24.82M 11.02M 16.33M 20.44M 11.24M
Total cash from operating activities 14.59M -6.26146M -4.51788M -5.25687M -4.18047M
Issuance of capital stock - 1.64M 0.71M 15.18M 13.54M
Depreciation 0.55M 0.35M 0.44M 0.26M 0.22M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.44068M -0.14682M -0.44541M -0.00848M -0.03394M
Change to account receivables 20.95M -23.25081M -0.01093M -0.11335M 0.04M
Sale purchase of stock - 1.64M 0.71M -0.66000M -0.66555M
Other cashflows from financing activities -0.16461M -0.14682M -0.18852M -0.05520M -0.36874M
Change to netincome 2.54M 0.52M 4.40M 1.78M 1.36M
Capital expenditures 0.63M 0.54M 0.19M 0.06M 0.37M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 20.51M -23.39763M -0.45634M -0.12182M 2.54M
Stock based compensation 2.49M 0.50M 4.30M 1.76M -
Other non cash items 20.29M 2.50M 4.08M 0.63M 5.63M
Free cash flow 13.96M -6.79648M -4.70640M -5.31207M -0.36874M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OCC
Orthocell Ltd
-0.01 0.83% 1.19 - - 46.24 14.87 41.27 -3.8756
CSL
CSL Ltd
1.50 0.63% 240.21 28.64 32.15 7.65 4.04 5.81 18.03
TLX
Telix Pharmaceuticals Ltd
-0.08 0.32% 24.92 166.67 57.47 10.68 14.73 10.52 89.03
MSB
Mesoblast Ltd
-0.03 1.80% 1.64 - 454.55 367.78 2.98 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd
0.10 0.80% 12.54 11.61 75.76 7.37 4.49 6.61 8.03

Reports Covered

Stock Research & News

Profile

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

Orthocell Ltd

Building 191, Murdoch, WA, Australia, 6150

Key Executives

Name Title Year Born
Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D. Exec. Chairman 1970
Mr. Paul Frederick Anderson CEO, MD & Exec. Director 1966
Ms. Leslie Wise J.D. Exec. Director NA
Ms. Nicole Jane Telford Chief Financial Officer NA
Mr. Alex McHenry Chief Operating Officer NA
Prof. Ming Hao Zheng Chief Scientific Officer and Member of Medical & Scientific Advisory Board NA
Mr. Simon Lee Robertson B.Bus, C.A., CA, M Appl. Fin. Company Sec. 1960
Mr. Paul Frederick Anderson CEO, MD & Executive Director 1966
Mr. Tony Macintyre Chief Manufacturing Officer NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. Company Secretary 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.